The Efficacy & Safety of the UAS Immunotherapy Protocol

Completed

Conditions studied: Perennial Allergic Rhinitis With Seasonal Variation

In brief

Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.

Key facts

Study ID

NCT01699659

Run by

United Allergy Services

People needed

60

Starts

2012-04-01

Expected to finish

2012-09-01

Last updated by the study team

2012-10-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy.

You may not qualify if…

• No beta blocker use,
• no pregnancy,
• no systemic steroids,
• no severe asthma/copd,
• no severe collagen vascular disorders,
• no neoplastic or uncontrolled seizure activity,
• no previous anaphylaxis, no significant cardiovsacular disease.

Where it is running

• UAS — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.